Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
Want to see IN:HESTERBIO full AI Analyst Report?
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,347.70
Previous CloseN/A
Volume2.45K
Average Volume (3M)308.00
Market Cap
₹17.60B
Enterprise Value₹19.38B
Total Cash (Recent Filing)₹281.58M
Total Debt (Recent Filing)₹2.14B
Price to Earnings (P/E)30.3
Beta0.54
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)52.41
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Multi-year Revenue GrowthConsistent multi-year revenue expansion, including a 2026 re-acceleration, indicates durable demand for veterinary vaccines and products. This supports scale advantages, more predictable production planning, and strengthens competitive position in poultry and livestock health markets over the medium term.
Improved Cash GenerationReturn to positive free cash flow that covered ~70% of net income in 2026 shows earnings converting into cash more reliably. Stronger cash generation supports capex, working capital needs, dividend capacity, and ability to pay down debt, improving financial resilience over coming quarters.
Deleveraging And Improving Capital StructureMeaningful reduction in debt-to-equity over recent years signals deliberate deleveraging and stronger equity base. Lower leverage reduces interest burden, improves debt capacity and financial flexibility, and positions the company to invest or weather cyclical pressures in the animal-health sector.
Bears Say
Margin And Cash-flow VolatilityLarge year-to-year swings in gross margins and net income have been persistent, creating unpredictability in earnings quality. Such volatility complicates budgeting, weakens stakeholder confidence, and raises execution risk for sustaining margins through input cost or demand shocks.
Weak Operating Cash Flow Coverage Of DebtOperating cash flow historically falls short of fully covering debt obligations, leaving coverage well below 1x in recent years. This constrained cash buffer limits ability to accelerate deleveraging or fund investments without relying on external financing in adverse scenarios.
Elevated Absolute Debt HistoryAlthough leverage has improved, the company retains a sizable absolute debt load and has a history of elevated leverage. In an earnings downturn this could restrict strategic options, increase refinancing risk, and pressure liquidity given the business's prior reliance on debt.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2347.70 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹17.60B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 55 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on May 15, 2026. The company reported ₹19.45 earnings per share for the quarter, beating the consensus estimate of N/A by ₹19.45.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹7 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹19.45 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.669%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
Technical Analysis
Gufic Biosciences Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
―
Unichem Laboratories Limited
―